ClinicalTrials.gg
Active, not recruitingNCT07673978Updated Jun 29, 2026

Effect of Ciprofol Injection on Postoperative Cognitive Function

A Phase 4 interventional study of Ciprofol group and Propofol group in Postoperative Cognitive Dysfunction, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Postoperative Cognitive Complications with a site in China — 14 open to participants now, 16 under way, none of them phase 3. Postoperative Cognitive Complications · China.

Planned enrollment
12th of 33
298 · median 220
Started
2026
with 3 others
Phase 4
10 of 57
2 open now
Primary completion
2026-12
later than 10 of 15 live
Registered
56th of 57
by date

Among the 57 studies in Postoperative Cognitive Complications with a site in China, this one is the 12th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 in phase 4, reaches primary completion later than 10 of the 15 other live ones, and was the 56th registered.

Postoperative Cognitive Complications

260 studies on the registry are indexed under Postoperative Cognitive Complications; 55 are open to participants now.

Browse Postoperative Cognitive Complications studies →

Open to participants now

14 of the 57 studies in Postoperative Cognitive Complications with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Postoperative Cognitive Complications studies recruiting now, 22 (65%) set no upper age limit and 4 (12%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Postoperative Cognitive Complications with a site in China, or all of them as a file.
02

Study summary

This study aims to explore the effect of ciprofol on the postoperative cognitive function of inpatients undergoing gastrointestinal endoscopy examination, to compare the anesthetic effects and differences in adverse reactions of propofol and ciprofol in gastrointestinal endoscopy , to compare the incidence of postoperative cognitive decline in patients undergoing gastrointestinal endoscopy examination between propofol and coprofol, and to optimize the anesthesia medication regimen for patients undergoing gastrointestinal endoscopy examination.

03

Conditions studied

  • Postoperative Cognitive Dysfunction
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-65 years old, I-Ⅲ, index: 18.5-30 kg/m ²
  2. Patients who plan to undergo gastroscopy or colonoscopy in our hospital
  3. The preoperative assessment of the MOCA scale in patients scheduled for elective surgery indicated normal cognitive function
  4. dextromanuality
  5. Voluntarily participate in this study and sign the form

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Patients who have had cardiovascular and cerebrovascular accidents in the past
  3. Patients with severe diseases of the cardiovascular system, respiratory system and liver and kidney system
  4. Patients with obstructive sleep apnea syndrome
  5. Patients with concurrent neurological or mental system diseases, or those with incomplete intellectual development
  6. Patients allergic to ciprofol or propofol drugs
  7. Patients with braking, visual/auditory impairments
  8. Patients with psychotropic drug addiction or alcohol dependence
  9. Patients who themselves or their attending physicians refused to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
298 participants (estimated)

Study arms

  • Experimental
    Experimental group (ciprofol)

    patients in the Ciprofol group will use ciprofol to complete the painless gastroscopy and colonoscopy treatment.

    Drug: Ciprofol group

  • Active comparator
    Control group (propofol)

    patients in the propofol group will use propofol to complete the painless gastroscopy and colonoscopy treatment.

    Drug: Propofol group

Interventions

  • patients in the Ciprofol group will use ciprofol to complete the painless gastroscopy and colonoscopy treatment.

  • patients in the propofol group will use propofol to complete the painless gastroscopy and colonoscopy treatment.

06

What researchers measure

Primary outcomes

  1. The difference in the incidence of cognitive function decline between ciprofol and propofol in patients undergoing painless gastroscopy and colonoscopy treatment

    Time frame: From the time the patient was enrolled in the study to 24 hours after the treatment

Secondary outcomes

  1. Intraoperative and postoperative adverse events

    Time frame: From the time the patient enters the operating room to 24 hours after the treatment

  2. Blood Pressure (mmHg)

    Non-invasive BP measured by cuff after entry and intermittently during surgery. Hypotension: SBP decrease \>30% from baseline; Hypertension: SBP increase \>30% from baseline.

    Time frame: From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

  3. Heart Rate (beats/min)

    Read from monitor. Bradycardia: \<50 bpm or decrease ≥25% from baseline; Tachycardia: \>100 bpm or increase ≥25% from baseline.

    Time frame: From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

  4. Respiratory Rate (breaths/min)

    Read from monitor or counted over 1 min. Respiratory depression: \<8 breaths/min lasting \>30 sec.

    Time frame: From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

  5. Oxygen Saturation (Pulse Oximetry)

    Read from monitor. Hypoxemia: SpO2 \<90% lasting \>15 sec.

    Time frame: From entering the operating room to leaving it (before anesthesia, after induction, and 5 minutes、10 minutes 、20 minutes 、30 minutes 、40 minutes、50 minutes、60 minutes after the operation began)

Other outcomes

  1. The dosage of propofol/ciprofol used

    Time frame: The dosage of drugs used during this period from anesthesia induction to the end of anesthesia (perioperative period) (approximately 25 - 60 minutes)

  2. The patient's stay time in the PACU(Post-Anesthesia Care Unit)

    The period from when the patients enter the PACU until they leave the PACU

    Time frame: up to 24 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 29, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07673978
Responsible party
Guangyou Duan (professor, The Second Affiliated Hospital of Chongqing Medical University) — Principal investigator
First posted
Jun 29, 2026
Start date
Jun 1, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Guangyou Duan
study director · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion